Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study - 11/08/23

Doi : 10.1016/j.clinre.2023.102150

Yinuo Yang ^a,^{^{1
These authors contributed equally to this work.}}, Xuemei Li ^a,^b,^{^{1
These authors contributed equally to this work.}}, Xinya Zhao ^c, Yiqing Liu ^d, Tong Zhao ^e, Qiang Zhu ^a,^⁎
^a Department of Gastroenterology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, 250021, China
^b Department of Gastroenterology, Heze Municipal Hospital, Heze, 274099, China
^c Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Ji'nan, 250021, China
^d Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Ji'nan, 250021, China
^e Qilu Hospital of Shandong University, Ji'nan, 250012, China

^⁎Corresponding author at: Department of Gastroenterology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Ji'nan, 250021, ChinaDepartment of GastroenterologyShandong Provincial HospitalCheeloo College of MedicineShandong UniversityJi'nan250021China

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Patients with chronic liver disease (CLD) are at a greater risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. This study investigated the antibody response to inactivated SARS-CoV-2 vaccination in a long-term prospective cohort of CLD patients. The seropositivity rates and antibody concentrations of anti-SARS-CoV-2 NAbs were similar among patients with different severity of CLD 6 months after the third vaccination. In addition, older CLD patients appeared to have lower antibody responses. These data might be helpful to inform vaccine decisions for patients with chronic liver disease.

Le texte complet de cet article est disponible en PDF.

Keywords : Chronic liver disease, SARS-CoV-2, Vaccine, Antibody response

Abbreviation : CLD, SARS-CoV-2, Non-ACLD, CACLD, DACLD, NAb, S/CO, IQR

Plan

Introduction

Materials and methods

Results

Discussion

Export

Vol 47 - N° 7

Article 102150- août 2023 Retour au numéro

Article précédent

Chronic hepatitis delta cirrhosis cured by adapting PEG-IFNα-2a + tenofovir disoproxil fumarate treatment duration until HBsAg loss
L. Yaici, G. Gatouillat, L. Andreoletti, Y. N'Guyen, M. Hentzien, E. Gordien, F. Bani-Sadr

| Article suivant

Acute hepatitis induced by Guduchi; Letter to the editor
Emilie Timmery, Quentin Binet, Benedicte Delire, Yves Horsmans

Bienvenue sur EM-consulte, la référence des professionnels de santé.

connectez-vous ou créez un compte

Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study - 11/08/23

Summary

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL